OBJECTIVES: To evaluate the role of GH in colon carcinogenesis, we examined the formation of aberrant crypt foci (ACFs) and tumor development in wild type (WT) and GH-deficient, spontaneous dwarf rats (SDRs) exposed to the carcinogen azoxymethane (AOM). DESIGN: ACF were quantified by stereomicroscopy and tumor number and weights were recorded for each animal. Cell proliferation was measured by vincristine metaphase arrest, flow cytometry, and bromodeoxyuridine (BrdU) incorporation. Apoptosis was measured by TUNEL staining and cleaved caspase-3 immunohistochemistry. IGF-I was measured by radioimmunoassay (RIA). Hexokinase activity was measured by spectrophotometric assay. PARP cleavage, and IGF-IR, and p27(kip/cip) expression were measured by Western blotting. RESULTS: ACFs detected by stereomicroscopy were markedly reduced ( approximately 85%) in SDRs vs. WT rats at 10, 25, and 28 weeks after AOM. Tumor incidence, number, and weight also were reduced in SDR vs. WT animals. AOM treatment increased cell proliferation in the distal colon (where tumors occur) of WT rats but not SDRs, and these changes corresponded to increased ACF and tumor formation. Apoptosis rates were similar in AOM-treated WT and SDRs. Alterations in serum IGF-I levels may contribute to differences in the proliferative response to AOM and decreased ACF formation in SDR vs. WT rats. CONCLUSIONS: We conclude that early neoplastic lesions (ACFs) were reduced in GH-deficient animals. This effect corresponds with differences in AOM-induced proliferation, but not apoptosis. These data indicate that GH is required for the full effect of AOM on colon ACF and tumor development, and that the SDR rat is a promising model for studies regarding the role of GH/IGF system in the initiation and promotion of colon cancer.
OBJECTIVES: To evaluate the role of GH in colon carcinogenesis, we examined the formation of aberrant crypt foci (ACFs) and tumor development in wild type (WT) and GH-deficient, spontaneous dwarf rats (SDRs) exposed to the carcinogen azoxymethane (AOM). DESIGN: ACF were quantified by stereomicroscopy and tumor number and weights were recorded for each animal. Cell proliferation was measured by vincristine metaphase arrest, flow cytometry, and bromodeoxyuridine (BrdU) incorporation. Apoptosis was measured by TUNEL staining and cleaved caspase-3 immunohistochemistry. IGF-I was measured by radioimmunoassay (RIA). Hexokinase activity was measured by spectrophotometric assay. PARP cleavage, and IGF-IR, and p27(kip/cip) expression were measured by Western blotting. RESULTS: ACFs detected by stereomicroscopy were markedly reduced ( approximately 85%) in SDRs vs. WT rats at 10, 25, and 28 weeks after AOM. Tumor incidence, number, and weight also were reduced in SDR vs. WT animals. AOM treatment increased cell proliferation in the distal colon (where tumors occur) of WT rats but not SDRs, and these changes corresponded to increased ACF and tumor formation. Apoptosis rates were similar in AOM-treated WT and SDRs. Alterations in serum IGF-I levels may contribute to differences in the proliferative response to AOM and decreased ACF formation in SDR vs. WT rats. CONCLUSIONS: We conclude that early neoplastic lesions (ACFs) were reduced in GH-deficient animals. This effect corresponds with differences in AOM-induced proliferation, but not apoptosis. These data indicate that GH is required for the full effect of AOM on colon ACF and tumor development, and that the SDR rat is a promising model for studies regarding the role of GH/IGF system in the initiation and promotion of colon cancer.
Authors: Robert E Schoen; Joel L Weissfeld; Lewis H Kuller; F Leland Thaete; Rhobert W Evans; Richard B Hayes; Clifford J Rosen Journal: Gastroenterology Date: 2005-08 Impact factor: 22.682
Authors: Carmen Z Michaylira; James G Simmons; Nicole M Ramocki; Brooks P Scull; Kirk K McNaughton; C Randall Fuller; P Kay Lund Journal: Am J Physiol Gastrointest Liver Physiol Date: 2006-03-30 Impact factor: 4.052
Authors: Ghenet K Hagos; Robert E Carroll; Tatiana Kouznetsova; Qian Li; Violeta Toader; Patricia A Fernandez; Steven M Swanson; Gregory R J Thatcher Journal: Mol Cancer Ther Date: 2007-08 Impact factor: 6.261
Authors: James M Amos-Landgraf; Jarom Heijmans; Mattheus C B Wielenga; Elisa Dunkin; Kathy J Krentz; Linda Clipson; Antwan G Ederveen; Patrick G Groothuis; Sietse Mosselman; Vanesa Muncan; Daniel W Hommes; Alexandra Shedlovsky; William F Dove; Gijs R van den Brink Journal: Proc Natl Acad Sci U S A Date: 2014-11-03 Impact factor: 11.205
Authors: James M Bugni; Leina Al- Rabadi; Kevin Jubbal; Iordanis Karagiannides; Gregory Lawson; Charalabos Pothoulakis Journal: Int J Cancer Date: 2011-11-17 Impact factor: 7.396
Authors: Robert E Carroll; Richard V Benya; Danielle Kim Turgeon; Shaiju Vareed; Malloree Neuman; Luz Rodriguez; Madhuri Kakarala; Philip M Carpenter; Christine McLaren; Frank L Meyskens; Dean E Brenner Journal: Cancer Prev Res (Phila) Date: 2011-03
Authors: Vera Chesnokova; Svetlana Zonis; Cuiqi Zhou; Maria Victoria Recouvreux; Anat Ben-Shlomo; Takako Araki; Robert Barrett; Michael Workman; Kolja Wawrowsky; Vladimir A Ljubimov; Magdalena Uhart; Shlomo Melmed Journal: Proc Natl Acad Sci U S A Date: 2016-05-25 Impact factor: 11.205